SUBSCRIBE TO TMCnet
TMCnet - World's Largest Communications and Technology Community

TMCNet:  Research and Markets: Global Testicular Cancer Drugs Market 2014-2018 With Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating

[April 16, 2014]

Research and Markets: Global Testicular Cancer Drugs Market 2014-2018 With Bristol-Myers Squibb, Hospira, Teva Pharmaceutical Industries & ZIOPHARM Oncology Dominating

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/cc3342/global_testicular) has announced the addition of the "Global Testicular Cancer Drugs Market 2014-2018" report to their offering.

One of the key drivers is the increasing prevalence of testicular cancer due to a variety of factors such as congenital abnormalities, family history, abnormal testicular development, and HIV infection. This has increased the demand for testicular cancer drugs as these drugs have greatly improved survival rate for patients with both seminomas and non-seminomas type of testicular cancer.

The current trend witnessed by the Global Testicular Cancer Drugs market is combination therapy being used for treating testicular cancer. Several oncologists believe that chemotherapy drugs are most effective when given in combination with radiation therapy and surgery. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapy helps in completely removing the tumor or destroying the cancerous cells in the patient's body. The combination therapy is decided depending on the size of the tumor and the risk of recurrence. Moreover, for treatment of testicular cancer, a combination of two or more drugs is usually given. Some of the combinations are BEP, EP (etoposide and cisplatin), and VIP (vinblastine plus ifosfamide and cisplatin).


Further, the report states that one of the main challenges in the market is the presence of alternative testicular cancer treatments that do not use drugs, thereby limiting the consumption of drugs.

Key vendors dominating this space include:

  • Bristol-Myers Squibb Co
  • Hospira Inc.
  • Teva Pharmaceutical Industries Ltd.
  • ZIOPHARM Oncology Inc.

Other vendors mentioned in the report are:

  • Baxter International Inc.
  • Fresenius Kabi Pharmaceuticals Holding Inc.
  • Mylan Pharmaceutical Inc.

Key Topics Covered:

  1. Executive Summary
  2. List of Abbreviations
  3. Scope of the Report
  4. Market Research Methodology
  5. Introduction
  6. Market Landscape
  7. Testicular Cancer by Type
  8. Testicular Cancer Disease by Stages
  9. Treatment Options
  10. Clinical Trial Snapshot
  11. Geographical Segmentation
  12. Buying Criteria
  13. Rate of Incidence and Prevalence
  14. Market Growth Drivers
  15. Drivers and their Impact
  16. Market Challenges
  17. Impact of Drivers and Challenges
  18. Market Trends
  19. Trends and their Impact
  20. Vendor Landscape
  21. Key Vendor Analysis

For more information visit http://www.researchandmarkets.com/research/cc3342/global_testicular


[ Back To Technology News's Homepage ]

OTHER NEWS PROVIDERS







Technology Marketing Corporation

800 Connecticut Ave, 1st Floor East, Norwalk, CT 06854 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments: tmc@tmcnet.com.
Comments about this site: webmaster@tmcnet.com.

STAY CURRENT YOUR WAY

© 2014 Technology Marketing Corporation. All rights reserved | Privacy Policy